CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOACaptura de pantalla 2022 09 14 a las 10.27.10    

Morphogenesis and neurodegeneration of the vertebrate Central Nervous System

Research summary:

The brain and other parts of the central nervous system (CNS), such as the retina, develop over a long period of time before reaching their final organization. Such a long period enables millions of neural cells to progressively acquire their specific identity and to progressively establish a precise network of functional connections among the generated cell types. Reaching such an elaborated organization is fundamental for our daily life and well-being. As we age, the brain again undergoes progressive changes but unfortunately “in the reverse direction”, making us less proficient. When these changes are drastic, as it happens in people suffering from Alzheimer’ disease or in individuals who becomes blind because their “photoreceptors” degenerate, performing even simple duties or relating to the immediate surroundings become impossible. Knowing how to have and preserve a healthy brain thus falls in between the comprehension of its development and the identification of the causes of its ageing. Our laboratory divides its research efforts between these two extremes. On one side we investigate a) how the visual system forms; on the other, b) we search the molecular causes underlying the brain alterations occurring in aging and/or Alzheimer ‘disease.

a) For over twenty years, our team has contributed to identify and study the molecular building blocks that coordinate the development of the vertebrate visual system. Building on this experience, we are now investigating how the retinal pigmented epithelium (RPE) forms and contributes to the overall architecture of the eye. The RPE consists of a monolayer of cells, positioned at the back of the neural retina. This tissue has the critical function of protecting, nourishing and cooperating with the light sensing cells of the retina: the photoreceptors. The cells of the RPE are initially neuroepithelial as those of the neural retina but soon transform in a cuboidal/squamous pigmented layer (Figure 1). The events underlying this transformation are still poorly understood. Using the zebrafish and chick embryos as models, we are studying the cellular and molecular aspects of this transformation and are further asking whether this transformation is necessary for the acquisition of the final cup-shape that the vertebrate eye has. In other words, we want to know what happens to the eye if the RPE does not develop correctly. As an extension of this question, we are also asking how the entire visual system adapts to the abnormal development of one of its parts. For example, what happens to the eye if the thalamic visual structures do not form in an appropriate manner?

b) When the brain ages, the number of functional connections among neurons decreases and the brain assume a state of low but chronic “inflammation”. These changes are exacerbated in neurodegenerative diseases such as Alzheimer’s Disease (AD), in which there is also an accumulation of typical “amyloid plaques” (Figure 2). From a molecular point of view, loss of connections, inflammation and amyloid plaque formation have a commonality: the activity of the metalloprotease ADAM10. We have recently shown that a small secreted protein, known as Secreted Frizzled Related Protein 1 (SFRP1), acts as an endogenous inhibitor of ADAM10. Based on this observation, we hypothesized that abnormally upregulated SFRP1 levels in the brain of AD patients could impair ADAM10 activity and be a common trait of AD. Our work has validated this hypothesis, demonstrating that SFRP1 contributes to AD pathogenesis, whereas neutralization of its activity in a mouse model prevents the progression of the disease and the loss of memory present in AD (or in aging). Based on this exciting result and taking advantage of different transgenic mouse models that we have generated, we are now investigating the direct implication of Sfrp1 in the loss of brain connections and in the inflammatory events that take place in AD and aging. We are further exploring the potential of SFRP1 neutralization as a therapeutic strategy against AD.

Image

Figure 1: Developing zebrafish retina in which the retinal pigmented epithelium is labelled in green whereas the contour of the neural retina cells is marked in purple. Nuclei of all cells are labelled in blue.

Image

Figure 2: Example of a human amyloid plaque positive for SFRP1 (red) and surrounded by microglial cells (green).

Image


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Albarrán VilchesAlejandro4264720Estudiante TFG
Battilossi Alessando4264720Estudiante TFG
Bovolenta NicolaoPaula4264718pbovolenta(at)cbm.csic.esE. Profesores de Investigación de Organismos Públicos de Investigación
Martín BermejoMª Jesús4264720cbermejo(at)cbm.csic.esTécnico Sup. Actividades Téc. y Profes. GP3
Martínez BañosMarcos4264720mmartinez(at)cbm.csic.esTitulado Sup. Actividades Tecn. y Prof.GP1
Miaja HernándezPablo4264720pablo.miaja(at)cbm.csic.esTitulado Sup. Actividades Tecn. y Prof.GP1
Osorio Sánchez-VilloriaJosé Manuel4264720Estudiante TFG
Pajda SzeligowskaEva4264720eva.pajda(at)cbm.csic.esM3 Predoc.formación
Pereyra GómezGuadalupe4264720gpereyra(at)cbm.csic.esM3
Pérez GarcíaVicente4264718vperez(at)cbm.csic.esE.Científicos Titulares de Organismos Públicos de Investigación
Pérez RamosAdrián4264720adrian.perez(at)cbm.csic.esDoctor FC3
Soto BajoIrene Cecilia4264720Estudiante TFG
Tabanera AnguitaNoemí4264720ntabanera(at)cbm.csic.esTitulado Sup. Actividades Tecn.y Prof.GP1

Relevant publications:

  • SFRP1 modulates astrocyte-to-microglia crosstalk in acute and chronic neuroinflammation. Rueda-Carrasco J, Martin-Bermejo MJ, Pereyra G, Mateo MI, Borroto A, Brosseron F, Kummer MP, Schwartz S, López-Atalaya JP, Alarcon B, Esteve P, Heneka MT, Bovolenta P. EMBO Rep. 2021 Sep 27:e51696. doi: 10.15252/embr.202051696. Online ahead of print. PMID: 34569685
  • Esteve P, Rueda-Carrasco J, Mateo, I, Martin-Bermejo MJ, Draffin, J, Pereyra, G, Sandonís A, Crespo I, Moreno I, Garcia-Esparcia P, Gomez-Tortosa E, Rabano A, Fortea J, Alcolea D, Lleo A, Heneka MT, Valpuesta, JM, Esteban, JA, Ferrer I, Dominguez M and Bovolenta P (2019) Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer’s disease pathogenesis. Nat Neurosci. 22, 1258-1268. (Editors’ choice in Sci. Transl. Med, 2019, 11, eaay7697)
  • Bertacchi M., Gruart, A., Kaimakis P., Allet C., Serra L., Giacobini P., Delgado-García JM., Bovolenta P., and Studer M. (2019) Mouse Nr2f1 haploinsufficiency unveils new pathological mechanisms of human BBSOA syndrome. EMBO Mol Med 11: e10291 (cover caption article)
  • Esteve P.* Crespo I.*, Kaimakis, P., Sandonís A. and Bovolenta P. (2019) Sfrp1 modulates cell-signaling events underlying telencephalic patterning, growth and differentiation. Cereb. Cortex 229, 1059–1074 (* co-authors)
  • Moreno-Marmol, T., Cavodeassi, F. and Bovolenta P. (2018). Setting eyes on the retinal pigment epithelium. Front Cell Dev Biol, 6, 145. doi: 10.3389/fcell.2018.00145.
  • Marcos S., Nieto-Lopez F., Sandonis A., Di Marco, F., Cardozo M., Esteve, P. and Bovolenta P. (2015) Secreted Frizzled Related Proteins modulate pathfinding and fasciculation of mouse retina ganglion cell axons by direct and indirect mechanisms. J. Neurosci. 35, 4729-4740 (cover caption article; Selected in The Faculty of 1000)
  • Marcos, S. González, M., Beccari, L., Carramolino, L., Martin-Bermejo MJ, Amarie O, Mateos-San Martín D., Torroja C, Bogdanovic O, Doohan R., Puk O, Hrabě de Angelis M, Graw J, Gomez-Skarmeta JL, Casares F, Torres M.*, and Bovolenta P.* (2015) Meis1 coordinates a network of genes implicated in eye development and microphthalmia. Development 142, 3009-3020 * co-senior authors
  • Cardozo M., Sánchez-Arrones L., Sandonis A., Sánchez-Camacho C., Gestri G., Wilson SW, Guerrero, I. and Bovolenta P. (2014) Cdon acts as a Hedgehog decoy receptor during proximal-distal patterning of the optic vesicle. Nature Comm. 5:4272. (Selected in The Faculty of 1000)
  • Sanchez-Arrones, L.*, Nieto-Lopez, F.*, Sanchez-Camacho, C, Carreres MI, Herrera, E, Okada, A Bovolenta, P. (2013) Shh/Boc signaling is required for sustained generation of ipsilateral-projecting ganglion cells in the mouse retina. J. Neurosci. 33, 8596-607 (Featured article) *Equally contributor
  • Esteve P., Sandonìs A., Cardozo M., Malapeira J., Ibañez C., Crespo I., Marcos S., Gonzalez-Garcia S., Toribio M.L., Arribas J., Shimono A., Guerrero I. and Bovolenta P. (2011). Sfrps act as negative modulators of ADAM10 to regulate retinal neurogenesis. Nat. Neurosci. 14, 562-569. (Selected in The Faculty of 1000)
  • Esteve, P., Sandonìs A., Ibañez C., Shimono A., Guerrero I. and Bovolenta P. (2011) Secreted Frizzled-Related Proteins are required for Wnt/βcatenin signalling activation in the vertebrate optic cup. Development 138, 4179-4184. (Featured article)

Doctoral theses:

  • Yap-Taz en la especificación del epitelio pigmentado de vertebrados. Carlos Camacho de la Macorra. Facultad de Ciencias, Universidad Autónoma de Madrid. Co-Dirección: Dr. Marcos Cardozo. En desarrollo.
  • Implicacion de Sfrp1 en envejecimiento cerebral. Guadalupe Pereyra. Facultad de Ciencias, Universidad Autónoma de Madrid. Co-Dirección: Dra. Pilar Esteve. En desarrollo.
  • Niveles elevados de SFRP1 en un modelo transgénico de raton desencadenan neuroinflamacion y perdida de memoria. Ines Mateos Ruiz. Facultad de Ciencias, Universidad Autónoma de Madrid. Co-Dirección: Dra. Pilar Esteve. Julio 2019. Sobresaliente Cum Laude.
  • Morphogenesis of the zebrafish retinal pigment epithelium and its involvement in optic cup formation. Tania Moreno. Marmol Facultad de Ciencias, Universidad Autónoma de Madrid. Co-Dirección: Dra. Florencia Cavodeassi. Junio 2019. Sobresaliente Cum Laude.
  • Sfrp1 promotes neuroinflammation through the modulation of ADAM10 proteolytic activity. Javier Rueda. Facultad de Ciencias, Universidad Autónoma de Madrid. Julio 2017, Co-Dirección: Dra. Pilar Esteve. Julio 2017. Sobresaliente Cum Laude.

Patents:

  • “Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of Alzheimer´s Disease”. Inventores: Paola Bovolenta, Pilar Esteve, Javier Rueda Carrasco, Maria Inés Mateo Ruiz, Maria Jesús Martin Bermejo (CSIC); Mercedes Dominguez Rodriguez Inmaculada Moreno Iruela (ISCIII). Ref. EP19382105

Distinctions:

  • Member of ERC Scientific Council
  • Member of Electo de EMBO
  • Research prize “Fundaluce”

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

COOKIES POLICY

What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers:

fondosocialeuropeo-300px.png
Ministerio-de-Ciencia-e-Innovacin-600px.png
Comunidad-de-Madrid-600Bpx.png
agenda20-30-600px.png
fundacion-areces600px0710.png
LOGO_ERC.jpg
hrexcellence.jpg
worldwidecancerresearch-600px0710.png
aecc-600tpx.png
bbva-fund-400.png
Niemann-Pick-400px.png
wilderfund-400px.png
AliciaKoplowitz-400px.png
la-caixa-fund-600px.png
inocente-inocente-600px.png
cure-alzheimers-fund-600px.png
citrin-foundation.png
tatiana-fund02-600bpx1.png
campus-excelencia-600x400px.png
fundacion-uno-entre-cien-mil-v02.png